NICE approve inhaled insulin for some patients

Inhaled insulin can be given to diabetics, but only those who struggle with injected insulin, according to NICE


Inhaled insulin can be given to diabetics, but only those who struggle with injected insulin, according to NICE.

The final appraisal document states that patients shown to have a severe phobia of insulin or those who have serious and persistent problems with injection sites, caused by lipohypertrophy, for example, would be eligible. Inhaled insulin can also be given if dietary changes, oral hypoglycaemic agents and insulin injections fail to control blood sugar.

Clinical trial findings indicate that inhaled insulin has similar effectiveness to short-acting subcutaneous insulin, said NICE.

But the high cost of inhaled insulin means it should not be routinely offered to diabetics.

Inhaled insulin should only be continued beyond six months if HbA1c improvements are deemed to be clinically beneficial.

But most GPs will not be responsible for initiating inhaled insulin therapy as it should begin and monitored at a specialist diabetes centre.

Andrea Sutcliffe, deputy chief executive of NICE, said: ‘We have also recommended further research takes place so we can better establish the place of this innovative approach to delivering insulin.’

Diabetes UK

Simon O’Neill, Director of Care at Diabetes UK said: 'Diabetes UK welcome the revised final guidance. It is a significant step forward from the initial recommendations following the consultation process.

‘We are pleased that needle phobias can now be diagnosed by a member of a diabetes care team rather than just mental health professionals. 

‘However, we still believe the potential benefits in reducing the risk of complications for those who delay moving on to insulin to avoid injections have not been adequately recognised. NICE have recognised that some people would prefer to use inhaled insulin. They have also recognised the improvement it can bring to quality of life and patient satisfaction. However, their decision has not taken all these factors into account for the wider diabetes population, and it still comes down to cost.

‘We do not want a repeat of the situation with insulin pumps.  Whilst other countries have enjoyed the benefits, we have fallen behind and access has been restricted.

‘The decision to prescribe Exubera should lie with the individual patient and his or her diabetes specialist.’

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

£20 notes spread out

VAT trap for PCNs could strip millions of pounds from general practice

Tens of millions of pounds could be stripped from general practice because work carried...

Talking General Practice logo

Podcast: Is the BMA representing GPs effectively, why GPs face a pension tax hit, and views on the workload crisis

In our regular news review the team discusses representation of GPs, a new survey...

Man sleeping

NICE guidance on insomnia backs app to replace sleeping pills

Hundreds of thousands of people with insomnia could be offered treatment via a mobile...

Health worker prepares a dose of COVID-19 vaccine

JCVI backs autumn COVID-19 booster campaign for high-risk adults and NHS staff

Frontline health and social care staff and adults at increased risk of severe illness...

GP consultation

Government accused of 'misleading' claims on general practice workforce

GP leaders have accused the government of making misleading claims about the general...

Consulting room door

LMC calls for enhanced access to be scrapped after abuse forces practice to close reception

A Midlands LMC has backed a practice forced to close its reception desk after abuse...